"While our pilot demonstrated that using UHF RFID technology at the unit, case and pallet level is feasible for track and trace purposes, a great deal of additional work needs to be undertaken by stakeholders across the industry to address significant challenges including global standards, privacy concerns and the safe handling of biologics. "Cardinal Health's test of RFID under real-world conditions has demonstrated that the technology has real promise to provide an added layer of safety," said Renard Jackson, vice president and general manager of global packaging services for Cardinal Health. It is also hoped that RFID data could improve efficiencies in the supply chain. Verifying the authenticity of medications along each step of the distribution process adds an additional layer of security to lessen the chance of counterfeit pharmaceuticals entering the supply chain. The pilot program tested whether ultra-high frequency (UHF) radio frequency identification (RFID) tags could be applied, encoded and read at normal production speeds during packaging and distribution of pharmaceuticals. Consequently, any such data, information, or opinions do not in any way represent a personal recommendation to any individual investor or any entities, whatever the type.Cardinal Health Inc., a leading provider of products and services supporting the health-care industry, on November 14 announced the results from the first end-to-end test of a technology that could further improve the safety and efficiency of the nation's pharmaceutical supply chain.
Nothing discussed or presented in Quantalytics constitutes a representation that any investment, investment strategy, or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation.ĭata, information, or opinions contained in Quantalytics in any form give no consideration to any particular individuals' investment needs or objectives, nor do they consider any individuals' financial condition. Quantalytics does not make any representations as to their accuracy or completeness. The data, information and opinions presented have been obtained or derived from sources believed by Quantalytics to be reliable. Any data, information, or opinions in Quantalytics in any form attributed to a third party represent Quantalytics’ interpretation of the data, information, or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. Any data, information, or opinions expressed in any form may change without notice. Any forward looking estimates presented by Quantalytics may prove to be incorrect and not be realized. All investments and investment recommendations entail risks. Such data, information, or opinions are not an offer to sell or to buy, or a solicitation to buy or sell any securities.
Any data, information, or opinions presented by Quantalytics are for general information purposes only.
Quantalytics is not a registered investment adviser, brokerage firm, or investment company. Q.ai, LLC is a wholly owned subsidiary of Quantalytics Holdings, LLC (“Quantalytics”). Q.ai is the trade name of Quantalytics Holdings, LLC.
0 kommentar(er)
